Caplyta
Caplyta is an atypical antipsychotic. While its exact mechanism is unknown, its efficacy is thought to be mediated through a combination of antagonist activity at 5-HT2A receptors and post-synaptic antagonist activity at central dopamine D2 receptors, along with moderate reuptake inhibition of serotonin.
Dosage by Body Weight
The recommended dose is 42 mg once daily, taken orally with or without food. No dosage titration is required. Dose reductions (e.g., to 10.5 mg or 21 mg) may be necessary when used with strong or moderate CYP3A4 inhibitors, or in patients with moderate to severe hepatic impairment.
- Body Weight
- Below 5 kg
- Dose
- Not indicated
- Frequency
- N/A
- Tracking Notes
- Safety and effectiveness of Caplyta in pediatric patients have not been established.
- Body Weight
- 5-7 kg
- Dose
- Not indicated
- Frequency
- N/A
- Tracking Notes
- Safety and effectiveness of Caplyta in pediatric patients have not been established.
- Body Weight
- 8-10 kg
- Dose
- Not indicated
- Frequency
- N/A
- Tracking Notes
- Safety and effectiveness of Caplyta in pediatric patients have not been established.
- Body Weight
- 11-15 kg
- Dose
- Not indicated
- Frequency
- N/A
- Tracking Notes
- Safety and effectiveness of Caplyta in pediatric patients have not been established.
- Body Weight
- 16-20 kg
- Dose
- Not indicated
- Frequency
- N/A
- Tracking Notes
- Safety and effectiveness of Caplyta in pediatric patients have not been established.
| Body Weight | Dose | Frequency | Tracking Notes |
|---|---|---|---|
| Below 5 kg | Not indicated | N/A | Safety and effectiveness of Caplyta in pediatric patients have not been established. |
| 5-7 kg | Not indicated | N/A | Safety and effectiveness of Caplyta in pediatric patients have not been established. |
| 8-10 kg | Not indicated | N/A | Safety and effectiveness of Caplyta in pediatric patients have not been established. |
| 11-15 kg | Not indicated | N/A | Safety and effectiveness of Caplyta in pediatric patients have not been established. |
| 16-20 kg | Not indicated | N/A | Safety and effectiveness of Caplyta in pediatric patients have not been established. |
Formulation
Purpose
Treatment of schizophrenia in adults, and treatment of depressive episodes associated with bipolar I or II disorder (bipolar depression) in adults as monotherapy or adjunctive therapy with lithium or valproate.
Generic Name
LumateperoneScheduled Drug
No. This medicine is generally not treated as a scheduled/prescription-only drug in common consumer references, but local rules may vary.